Skip to main content
Journal cover image

The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data.

Publication ,  Journal Article
Horning, SJ; Chao, NJ; Negrin, RS; Hoppe, RT; Kwak, LW; Long, GD; Stallbaum, B; O'Connor, P; Blume, KG
Published in: Ann Oncol
January 1991

Seventy-seven Hodgkin's disease and non-Hodgkin's lymphoma (NHL) patients received high-dose etoposide in combination with cyclophosphamide and either fractionated total body irradiation (TBI) (n = 28) or carmustine (n = 49) prior to autologous bone marrow transplantation. Marrow from NHL patients was purged in vitro with a panel of monoclonal B- and T-cell antibodies and complement. Six toxic deaths (8%) occurred, all in patients who received carmustine. With a median follow-up of 1 year, 57 patients are alive and free from progressive disease. The 1-year actuarial survival and freedom from progression are 85 and 73% in fractionated TBI/etoposide/cyclophosphamide-treated patients and 79 and 72% in carmustine/etoposide/cyclophosphamide-treated patients. Forty-five of these patients participated in prospective trials for which eligibility criteria were (1) less than 25% curability with conventional therapy; (2) achievement of minimal disease state with conventional therapy; and (3) transplantation early in the course of disease. One-year actuarial survival for 18 patients with relapsed Hodgkin's disease is 80% and for 21 relapsed intermediate and high-grade NHL patients, 70%. One NHL Burkitt's patient was transplanted on a protocol for high-risk intermediate and high-grade NHL in first remission. Five patients with follicular mixed or small cleaved NHL were also transplanted in first remission.

Duke Scholars

Published In

Ann Oncol

DOI

ISSN

0923-7534

Publication Date

January 1991

Volume

2 Suppl 1

Start / End Page

47 / 50

Location

England

Related Subject Headings

  • Whole-Body Irradiation
  • Transplantation, Autologous
  • Prospective Studies
  • Oncology & Carcinogenesis
  • Lymphoma, Non-Hodgkin
  • Humans
  • Hodgkin Disease
  • Follow-Up Studies
  • Etoposide
  • Drug Evaluation
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Horning, S. J., Chao, N. J., Negrin, R. S., Hoppe, R. T., Kwak, L. W., Long, G. D., … Blume, K. G. (1991). The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data. Ann Oncol, 2 Suppl 1, 47–50. https://doi.org/10.1093/annonc/2.suppl_1.47
Horning, S. J., N. J. Chao, R. S. Negrin, R. T. Hoppe, L. W. Kwak, G. D. Long, B. Stallbaum, P. O’Connor, and K. G. Blume. “The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data.Ann Oncol 2 Suppl 1 (January 1991): 47–50. https://doi.org/10.1093/annonc/2.suppl_1.47.
Horning, S. J., et al. “The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data.Ann Oncol, vol. 2 Suppl 1, Jan. 1991, pp. 47–50. Pubmed, doi:10.1093/annonc/2.suppl_1.47.
Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Kwak LW, Long GD, Stallbaum B, O’Connor P, Blume KG. The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data. Ann Oncol. 1991 Jan;2 Suppl 1:47–50.
Journal cover image

Published In

Ann Oncol

DOI

ISSN

0923-7534

Publication Date

January 1991

Volume

2 Suppl 1

Start / End Page

47 / 50

Location

England

Related Subject Headings

  • Whole-Body Irradiation
  • Transplantation, Autologous
  • Prospective Studies
  • Oncology & Carcinogenesis
  • Lymphoma, Non-Hodgkin
  • Humans
  • Hodgkin Disease
  • Follow-Up Studies
  • Etoposide
  • Drug Evaluation